Articles dans des revues avec comité de lecture (270)
168.
Choufani, G., Nagy, N., Saussez, S., Marchant, H., Bisschop, P., Burchert, M., Danguy, A., Louryan, S., Salmon, I., Gabius, H.-J., Kiss, R., & Hassid, S. (1999). The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer, 86(11), 2353-2363. doi:10.1002/(SICI)1097-0142(19991201)86:11<2353::AID-CNCR25>3.0.CO;2-A171.
Vanmuylder, N., Evrard, L., Louryan, S., Glineur, R., Rooze, M., & Dourov, N. (1999). HSP110: new marker for apoptosis. Cell biology international.172.
Evrard, L., Vanmuylder, N., Glineur, R., Louryan, S., Rooze, M., Malevez, C., Deroux, E., Vervaet, C., & Daelemans, P. (1999). Apoptose, HSP’s, développement cranio-facial normal et tératologique. Belgium News in Stomatology and Maxillo-facial Surgery.173.
Glineur, R., Louryan, S., Lemaitre, A., Evrard, L., Rooze, M., & De Vos, L. (1999). Cranio-facial dysmorphism: experimental study in the mouse, clinical applications. Surgical and radiologic anatomy, 21(1), 41-47.174.
Evrard, L., Vanmuylder, N., Dourov, N., Glineur, R., & Louryan, S. (1999). Cytochemical identification of HSP110 during early mouse facial development. Journal of craniofacial genetics and developmental biology, 19(1), 24-32.